High Content Screening Market, By Product Type (Cell Imaging and Analysis Equipment, Consumables, HCS Software, HCS Services), By Application (Primary Screening, Target Identification & Validation, Toxicity Studies, Compound Profiling, Others), By End User (Pharmaceutical Organizations, Biotechnology Organizations, Research Institutes, Independent CRO, Government Organizations, Others), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018 - 2030

Published In : Jun 2023

Code : CMI3487

Pages :167

Formats :

Excel and PDF

Industry : Clinical Diagnostic

High Content Screening MarketSize and Trends

The global high content screening market is estimated to be valued at US$ 1,847.2 million in 2023 and is expected to exhibit a CAGR of 5.8% during the forecast period (2023-2030).

Increasing research and development activities is expected to drive the market growth over the forecast period. High Content Screening can answer biological questions in the pharmaceutical industry and academia. In vitro toxicology including developmental toxicity, genotoxicity, developmental neurotoxicity/neurotoxicity, hepatotoxicity, cardiotoxicity, and nephrotoxicity utilizes HCS techniques. Several newly developed cellular assay models including induced pluripotent stem cells (iPSCs), three-dimensional (3D) cell models, and tissues-on-a-chip techniques are made possible. Genome editing technologies (e.g., CRISPR/Cas9), data analyzing tools for imaging, and coupling with high-content assays also make use of HCS. These approaches offer a huge step forward in dissecting biological processes, developing drugs, and making toxicology studies easier.

Figure 1. Global High Content Screening Market Value (US$ Million), By Region, 2023

R&D in drug discovery is expected to propel growth of the global high content screening (HCS) market over the forecast period. For instance, in February 2020, researchers from Purdue University, a public land-grant research university, reported assessment of the effects of IL-27 – a heterodimeric cytokine composed of subunits IL-27p28 and EBI3 (Epstein–Barr virus-induced gene 3) – on the gene expression changes of TC2R prostate adenocarcinoma cells. HCS was used to identify RNAi (RNA interference) that cut down messenger RNAs that code those specific proteins which caused changes on the gene expression changes of TC2R prostate adenocarcinoma cells.

Moreover, increasing investment in HCS is expected to aid in growth of the market. For instance, in January 2020, St. Jude Children’s Research Hospital invested US$ 13.4 million for building a laboratory resource center, which will include two new labs, the Center for Modeling Human Pediatric Diseases and High Content Screening.

Figure 2. Global High Content Screening Market Value (US$ Million), By Product Type , 2023

HCS Cross sectional analysis :

By end user, pharmaceutical and biotechnological segment is set to dominate in North America due to the presence of key players such as Agilent Inc, Millipore , Bio-rad labs , and Tecan Group Ltd.